WHO WE ARE
Creative Medical Technology Holdings, Inc.
Ticker Symbol CELZ
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company committed to improving patient lives in the areas of Immunology, Urology, Neurology and Orthopedics.
Creative Medical Technology Holdings, Inc. (CELZ) is focused on regenerative medical solutions for unmet Immunological, Urological, Neurological and Orthopedic needs. We have developed an extensive intellectual property portfolio utilizing stem cells and interrelated technologies for the treatment of multiple indications and commercialized complete patented and trademarked protocols for erectile dysfunction under the CaverStem® brand and the FemCelz® brand for the treatment of female sexual dysfunction. Our StemSpine® technology has undergone a pilot study and is prepared for commercialization of it’s autologous (patients own stem cells) program with the vision of progressing it’s patented allogenic (donor cells) program through FDA clinical trial. CELZ is also breaking new ground with its ImmCelz® technology for the treatment of multiple indications. Our team consists of leading physicians and scientists specializing in regenerative medicine. Our “science-first” approach to procedures ensures that all of our technology is proven to be both safe and effective.
The Creative Medical Technology Holdings Difference
Commercialized Procedures (CaverStem® and FemCelz®)
Extensive Patent Portfolio
Key Relationships With Leading Scientists and Physicians
Validated Safety and Efficacy
Intellectual Property
Creative Medical Technology Holdings has developed/acquired a robust intellectual property (IP) portfolio related to the utilization of stem cells to improve patient lives in the areas of Urology, Neurology and Orthopedics.
This IP portfolio positions us at the forefront of the regenerative medicine industry (set to grow to $39Bn by 2023). We plan to commercialize these products on our own and in collaboration with strategic partners.
| Areas | Patent | Description |
|---|---|---|
| Urology | US20180015127A1 | Methods for Treatment of Premature Ovarian Failure and Ovarian Aging Using Regenerative Cells |
| Urology | US8372797B2 | Treatment of Erectile Dysfunction by Stem Cell Therapy |
| Urology | US20180325959A1 | Methods of Treating Erectile Dysfunction Using Regenerative Cells and Therapeutic Energy Treatments |
| Neuro/Oncology | US20190022147A1 | Treatment of Glioma by Amniotic Fluid Stem Cells and Exosomes Derived Thereof |
| Neurology | US20180340145A1 | Generation of Autologous Immune Modulatory Cells for Treatment of Neurological Conditions |
| Stem Cells | US7569385B2 | Multipotent Amniotic Fetal Stem Cells |
| Orthopedics | US20180344899A1 | Enhancement of Nucleus Pulposus Regeneration by Enhanced Perfusion of Perispinal Area by Combination Drug, Gene and Cellular Therapies |
| Orthopedics | US20180360882A1 | Perispinal Perfusion by Administration of T Regulatory Cells Alone or in Combination with Angiogenic Cell Therapies |
| Orthopedics | US9598673B2 | Treatment of Disc Degenerative Disease |
| Immunotherapy | US63123380 | Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells |
| Immunotherapy | US62510,203. | Generation of Autologous Immune Modulatory Cells for Treatment of Neurological Conditions |
| Immunotherapy | US63132472 | Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells |
| Immunotherapy | US63138776 | Treatment of Diabetes Using Immune Cells Reprogrammed Ex Vivo by Regenerative Cells |
| Immunotherapy | US63138576 | Treatment of Liver Failure by Ex Vivo Reprogrammed Immune Cells |
| Immunotherapy | US63149671 | Treatment of Chronic Rejection and Concurrent Induction of Transplantation Tolerance by Ex Vivo Altered Immune Cells |
Timothy Warbington
Chief Executive Officer
Donald Dickerson
Chief Financial Officer
Thomas Ichim PhD
Chief Scientific Officer
Timothy Warbington
Donald Dickerson
Thomas Ichim PhD
Amit Patel MS MD
Camillo Ricordi, MD
Is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute and the Cell Transplant Center.
Boris Reznik A.S. M.S. Ph.D. – SAB
Boris Reznik is the Chairman of Venvalo Group. During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed high growth, profitable enterprises and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in multiple technology-based companies and has participated in many public and private fundings and mergers and acquisitions of technology-based companies, ranging from Millions to Billions.
Timothy Henry MD
Director of Cardiology, Christ Hospital, Cincinnati, OH. Dr. Henry’s experience also includes Director of Research at Minneapolis Heart Institute Foundation.
Santosh Kesari, MD, PhD
Director, Neuro-oncology; Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute
Our Pipeline
Product
Description
CaverStem®
Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men
FemCelz®
Regenerative Stem Cell Procedure for Treatment of Female Sexual Dysfunction
StemSpine®
Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease
ImmCelz®
Amniotic Fluid Derived Stem Cells for Treatment of Stroke
OvaStem®
Stem Cell Treatment for Premature Ovarian Failure
MEDIA
Creative Medical Technology Holdings Inc.
/PRNewswire/ -- (OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today filing of a patent application covering the use of ImmCelz®...
Creative Medical Technology Holdings Inc.
We've been asked to become active again on Twitter. Excellent suggestion. We are vetting candidates for a social media position within the company. Should any
Creative Medical Technology Holdings Inc.
To our shareholders, we too are eagerly waiting for an FDA response to our IND application for the treatment of stroke. We have not received
Creative Medical Technology Holdings Inc.
finance.yahoo.com/news/creative-medical-technology-holdings-identifies-124500808.html
(OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female infertility/ovarian failure treatment. OvaStem®, which is covered by issued patent #10,792,310, involves injection of stem cells into dysfunctional ovaries and h...
Creative Medical Technology Holdings Inc.
The company has received inquiries about our license for the JadiCell. As reflected in our public disclosures, CELZ does have a license for the JadiCell
Creative Medical Technology Holdings Inc.
finance.yahoo.com/news/creative-medical-technology-holdings-files-124500550.html
(OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney failure in an animal model. Using the classical "ischemia/reperfusion" system, collaborators of the Com...
Creative Medical Technology Holdings Inc.
/PRNewswire/ -- Creative Medical Technology Holdings Inc., (OTC – CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz®...
Creative Medical Technology Holdings Inc.
/PRNewswire/ -- (OTC – CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a model of...
Creative Medical Technology Holdings Inc.
/PRNewswire/ -- (OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food...
Creative Medical Technology Holdings Inc.
finance.yahoo.com/news/creative-medical-technology-holdings-identifies-124500811.html
RESEARCH COLLABORATIONS
We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.
For inquiries, please contact the company: TimW@CreativeMedicalTechnology.com
